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Mild therapeutic hypothermia for 
patients with acute coronary syndrome 
and cardiac arrest treated with 
percutaneous coronary  
intervention (UNICORN). The design 
and rationale for the prospective, 
observational, multicenter study
ABSTRACT
Introduction. Cardiac arrest constitutes the most frequent reason for sudden death in developed coun-
tries. Out-of-hospital cardiac arrest (OHCA) survivors are at high risk of death or neurologic deficits. The existing 
data regarding effectiveness and safety of mild therapeutic hypothermia (MTH) for treatment of OHCA survivors 
are inconsistent and ambiguous. Moreover, a uniform protocol of treatment by means of MTH is lacking.
Methods. The UNICORN study is a phase IV, prospective, international, multi-centre, observational study 
designed to assess the effectiveness of MTH in patients after OHCA with shockable rhythm presenting 
with acute coronary syndrome (ACS). The trial is expected to include up to 500 patients. Depending on 
the availability of MTH in each study centre, besides the routine treatment of ACS in OHCA survivors, 
patients will either undergo MTH according to a uniform protocol or will not undergo MTH (250 patients per 
group). The primary end-point of the study is all cause mortality at 180 days after enrolment. Secondary 
end-points include: neurological outcome at discharge, stent thrombosis at 30 days, bleeding according to 
the BARC criteria, infectious complications at 180 days, and rhythm and conduction disorders at 180 days. 
Ethics and dissemination. The study received approval from the Local Ethics Committee to conduct the 
study (Komisja Bioetyczna Uniwersytetu Mikołaja Kopernika w Toruniu przy Collegium Medicum im. Lud-
wika Rydygiera w Bydgoszczy; study approval reference number KB 615/2015). The study results will be 
disseminated through conference presentations and publications in peer-reviewed journals.
Trial registration. ClinicalTrials.gov identifier: NCT02611934 (18 November 2015). 
Key words: acute coronary syndrome, out-of-hospital cardiac arrest, percutaneous coronary intervention, 
therapeutic hypothermia
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Introduction
Cardiac arrest constitutes the most frequent reason 
for sudden death in developed countries. It is estimat-
ed that each year between 275,000 and 235,000 to 
325,000 new cases of out-of-hospital cardiac arrest 
(OHCA) occur in Europe and the United States respec-
tively [1, 2]. The rate of admission to hospital after a suc-
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cessful return of spontaneous circulation in adult OHCA 
patients is estimated to be approximately 15% [3].
Unconscious patients admitted to intensive care 
units after OHCA are at high risk of death or neurologic 
deficits. The existing data regarding effectiveness and 
safety of mild therapeutic hypothermia (MTH) for the 
treatment of OHCA survivors are inconsistent. 
Two relatively small randomized trials involving 
patients who remained unconscious after resuscitation 
from cardiac arrest of presumed cardiac cause with 
an initial shockable rhythm, compared therapeutic 
hypothermia (32°C to 34°C for 12 to 24 hours) with 
standard treatment. These studies showed a significant 
improvement in neurologic function and survival rates 
in patients treated with therapeutic hypothermia [4, 5]. 
According to the current European Society of Cardiolo-
gy (ESC) guidelines for the management of ST-elevation 
myocardial infarction, MTH is indicated early after re-
suscitation of cardiac arrest patients who are comatose 
or in deep sedation (class of recommendation I, level 
of evidence B) [6].
Dumas et al. performed a cohort study aimed at as-
sessing the influence of percutaneous coronary interven-
tion (PCI) and therapeutic hypothermia on a long-term 
prognosis in resuscitated patients following OHCA [7]. 
MTH was applied in 241 out of 941 (25.6%) OHCA 
survivors comatose at hospital admission. The highest 
survival rate was observed in patients treated with hypo-
thermia and concomitant PCI, while the worst outcomes 
were observed in patients who did not obtain any of these 
therapeutic methods. The authors concluded with the 
suggestion that the effects of acute hospital interventions 
for post-resuscitation treatment extend beyond hospital 
survival and can positively influence prognosis following 
the arrest hospitalization [7]. As none of the investigated 
methods (PCI or hypothermia) used separately was as 
effective as the combination of both, we assumed that 
concomitant use of PCI and MTH is probably the optimal 
therapeutic approach to resuscitated patients with acute 
coronary syndrome (ACS) after OHCA.
A cohort study by Casella et al. provided a similar 
message [8]. MTH was performed in 141 (51%) out 
of 278 comatose patients after OHCA. The authors 
demonstrated that in comatose patients resuscitated 
after OHCA emergency coronary angiography with 
PCI, if indicated, in combination with MTH is associated 
with good neurologic outcomes and improved survival 
rates as compared with non-invasively managed cas-
es. However, a more detailed analysis using a propen-
sity-matched comparison and a multivariable analysis 
has not confirmed such benefits. Thus, these findings 
question the independent effect of the mentioned 
interventions and raise the possibility that the associ-
ation of coronary angiography or PCI with a positive 
outcome, observed by others, could depend more on 
the pre-selection of a lower risk population that receives 
optimal post-OHCA care than on the benefits of early 
revascularization [8].
Favourable effect of MTH on survival and neurolog-
ical outcome was confirmed in meta-analysis pooling 
data from randomized and non-randomized studies 
and in a recently published observational study with the 
historical control group [9, 10]. However, the results of 
the TTM trial (The Targeted Temperature Management 
Trial), the biggest available randomized study, are 
contradictory. Comparison of two treatment regimens: 
MTH at a targeted temperature of 33°C versus fever 
prevention at a targeted temperature of 36°C in coma-
tose patients after OHCA did not provide any evidence 
of the superiority of MTH [11].
We found the methodology of this trial questionable, 
as there were significant limitations related to protocol 
and study conduction [11]. The protocol limitations 
were related to the non-uniform methodology of cooling 
and heterogeneous population of the trial. The intravas-
cular cooling was used only in 24% of patients, while the 
remaining patients were cooled with surface method. 
The study population comprised 40% of patients with 
myocardial infarction, while myocardial necrosis was 
not confirmed in the remaining subjects. Moreover, 
there were also serious limitations related to the trial 
conduction. The target temperature was not reached 
in a substantial number of patients in the MTH arm as 
showed by the mean temperature during hypothermia. 
Huge dispersion of temperature during hypothermia 
exceeding 3°C was observed. The duration of the induc-
tion phase of hypothermia was unacceptably long with 
a mean of 8 hours [11]. These important shortcomings 
of the trial could have negatively affected its results.
Our own experience showed a 26% mortality rate 
in patients after OHCA treated with MTH and 54% in 
the control group (p = 0.005; NNT = 3.55) [12], while 
in the TTM study, death occurred in 48% and 47% (ns) 
of patients respectively [11]. In our previous study, 
favourable neurological outcome was observed in 49% 
of MTH patients and in 26% of patients in the control 
group (p = 0.032; NNT = 4.24) compared with 46% 
and 48% (ns) in the TTM trial respectively. In our former 
trial [12], the intravascular cooling method was used in 
all 69 MHT patients with support of cold saline infusion 
(4°C) and ice packs at the induction of MTH compared 
with intravascular cooling applied only in 24% of the 
TTM study population with no defined induction proto-
col (at the discretion of the sites participating in the trial) 
as reported by Nielsen et al. [11]. Target temperature of 
33°C was reached 4 hours after the initiation of MTH in 
our study (the mean in the study population), while in the 
TTM study the stabilization of temperature (above 33°C) 
was observed after 8 hours, and the lowest temperature 
(still above 33°C) after 17 hours. In both studies, the ab-
solute temperature reduction in MTH patients amounted 
to 3.5°C and less then 2°C, and concomitant PCI during 
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hypothermia induction was performed in 75% and 42% 
of MTH patients respectively [11, 12].
In our cohort the following features were determined 
as independent predictors of in-hospital survival with 
favourable neurological outcome: OHCA with shock-
able rhythm (OR 12.36, CI 95% 1.15–132.4, p = 0.035), 
treatment with MTH (OR 4.65, CI 95% 1.19–18.25, 
p = 0.0250), reanimation duration (OR 0.57, CI 95% 
0.38–0.85, p = 0.005) and age (OR 0.41, CI 95% 0.25– 
–0.69, p = 0.0006) [12]. Substantial differences between 
the results of the above mentioned studies strongly 
suggest that careful patient selection and proper con-
duction of MTH procedure may have a pivotal impact on 
the results of resuscitated patients after OHCA [11, 12].
We hypothesized that careful selection of patients 
with shockable rhythm and proper conduction of MTH 
procedure including quick induction up to the target 
temperature may improve clinical outcomes in resus-
citated patients with diagnosed or suspected ACS 
after OHCA treated with concomitant PCI, if feasible. 
Therefore, we have proposed to conduct a prospective, 
observational, multicentre study Mild Therapeutic Hypo-
thermia for Patients with Acute Coronary Syndrome and 
Cardiac Arrest Treated with Percutaneous Coronary 
Intervention (UNICORN) [13]. 
Methods
Study objectives
The UNICORN study is designed to determine 
whether MTH applied in patients with ACS and car-
diac arrest treated with PCI is associated with better 
clinical outcomes as compared with standard therapy 
without MTH. 
Study design 
The UNICORN trial is a phase IV, prospective, inter-
national, multi-centre, observational study. The study 
population includes unconscious subjects after OHCA 
with shockable rhythm presenting with ACS. After admis-
sion to one of the study centres and confirmation of the 
initial diagnosis, patients will be screened for eligibility 
for the study. Two types of study centres will participate 
in the trial: centres with and centres without MTH avail-
able. All study participants enrolled in centres with MTH 
available will be treated with MTH in addition to standard 
therapy, according to the protocol described below, 
and all study patients enrolled in centres without MTH 
available will be treated without this procedure (Fig. 1). 
The expected enrolment is 500 patients (250 patients 
per group). Apart from medical interventions related to 
MTH, all patients in both study groups will be treated 
according to the same strategy (including in-hospital 
treatment, rehabilitation and long-term maintenance 
therapy). The planned follow-up is 180 days. 
Study population
All adult patients with the score of ≤ 8 on the 
Glasgow Coma Scale on admission to the hospital after 
OHCA with diagnosed or presumed ACS and shockable 
initial rhythm will be screened with regard to inclusion 
and exclusion criteria of the trial.
Figure 1. Flow chart of the UNICORN study; ACS — acute coronary syndromes; MTH — mild therapeutic hypothermia; 
OHCA — out-of-hospital cardiac arrest; PCI — percutaneous coronary intervention
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Inclusion criteria
The inclusion criteria are: 1) age ≥ 18 years, 2) OHCA 
survivor, 3) sustained return of spontaneous circulation 
(ROSC) for more than 20 minutes after resuscitation, 
4) unconsciousness with the score of ≤ 8 on the 
Glasgow Co+ Scale after ROSC, 5) shockable initial 
rhythm, 6) diagnosis or suspicion of ACS. 
Exclusion criteria
The exclusion criteria include: 1) unwitnessed 
OHCA, 2) obvious or suspected pregnancy, 3) known 
serious infection before OHCA, 4) known bleeding di-
athesis, 5) confirmed or suspected internal bleeding, 
6) confirmed or suspected acute stroke, 7) confirmed or 
suspected cerebral injury, 8) known serious neurolog-
ical dysfunction before OHCA (Cerebral Performance 
Category [CPC] ≤ 4), 9) known serious disease mak-
ing 180 days of survival unlikely, 10) hemodynamic 
instability with systolic blood pressure < 65 mm Hg 
despite the treatment, 11) time delay from ROSC to 
MTH induction > 240 minutes, 12) asystole or pulseless 
electrical activity as the initial rhythm, 13) initial body 
temperature < 30°C. 
Treatment
The induction of MTH will be performed with the 
infusion of a cold saline (0.9% solution of sodium 
chloride at the temperature of 4°C) and the usage of 
ice packs. MHT will be maintained with a MTH-ded-
icated catheter introduced into the inferior vena 
cava through the femoral vein by the interventional 
cardiologist during coronary angiography. MTH will 
be maintained for at least 12 hours, with an expected 
duration of 24 hours at the target temperature of 
33°C. The rewarming phase will be conducted in 
an actively controlled manner (0.3°C per hour). The 
patient’s core temperature will be independently 
measured in the urinary bladder as well as in the 
lower one third of the oesophagus using a dedicated 
catheter and tube. 
All patients treated with MTH will be mechanically 
ventilated with a concomitant continuous intravenous 
infusion of propofol and fentanyl for sedation and 
analgesia. 
During their participation in the study, all patients will 
be treated according to the current ESC guidelines. The 
choice of the access of the coronary invasive procedure 
(radial or femoral) and the type of implanted stent will 
be at the discretion of an operator. Moreover, standard 
therapy will include aspirin, P2Y12 receptor inhibitor, 
beta blockers, statins, and angiotensin-converting 
enzyme inhibitors or angiotensin II receptor blockers, 
if not contraindicated.
Study end-points
The primary end-point of the study is all cause 
mortality at 180 days after enrolment. Secondary 
end-points include: 1) neurological outcome defined 
according to CPC at discharge, 2) stent thrombosis at 
30 days, 3) bleeding according to the BARC criteria, 
4) infectious complications at 180 days, 5) rhythm 
and conduction disorders at 180 days. Patient risk 
stratification assessment will be performed according 
to plasma concentrations of natriuretic peptides (BNP 
or NTproBNP), ST2 and adrenomedullin at enrolment 
into the study [14–16].
Statistical analysis 
The continuous variables in both study groups 
will be compared by means of the t-test for normally 
distributed values as assessed by Kolmogorov-Smirn-
ov test. Otherwise, the Mann-Whitney U test will be used. 
Proportions will be compared by the chi-square test 
when appropriate. Survival analysis will be performed 
by the Kaplan-Meier method with log-rank test group 
comparison. 
Determination of sample size
We estimated that a sample of 454 patients would 
provide 90% power to detect a 30% reduction in the 
hazard ratio for death in the MTH group as compared 
with control group, at a two-sided alpha level of 0.05. To 
detect a hazard ratio of death reduction of 30%, with 
the assumption of mortality of 35% in the MTH group 
versus 50% in the control group, a sample of 227 pa-
tients per group would be needed. On the basis of these 
assumptions, a sample of 500 patients was chosen to 
allow for a drop-out of 46 patients.
Ethics and dissemination
Ethics
The study received a favourable ethical opinion and 
approval from the Local Ethics Committee to conduct 
the study (Komisja Bioetyczna Uniwersytetu Mikołaja 
Kopernika w Toruniu przy Collegium Medicum im. 
Ludwika Rydygiera w Bydgoszczy; study approval 
reference number KB 615/2015).
The study will be conducted in accordance with the 
principles contained in the Declaration of Helsinki. In ac-
cordance with national requirements and the principles 
of the Declaration of Helsinki, written informed consent 
will be waived, delayed, or obtained from a legal surro-
gate, depending on the circumstances, and will be ob-
tained from each patient who regained mental capacity.
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Present status
The approval of the Local Ethics Committee was 
obtained on September 29, 2015. On November 18, 
2015 the UNICORN study was registered on Clinical-
Trials.gov (ClinicalTrials.gov identifier: NCT02611934) 
The first patient is expected be enrolled in March 
2016. We plan to complete the study enrolment in 
March 2018.
Dissemination of results
Treatment of all enrolled patients will be supervised 
online and consulted, if necessary, by UNICORN Clin-
ical Committee. Data from all the study centres will be 
collected and analysed by central UNICORN Coordi-
nating Laboratory.
The study results will be disseminated through con-
ference presentations and peer-reviewed journals. The 
results will also be available to all participating clinicians 
to ensure the optimal care in OHCA patients.
Summary
The data on the efficacy of MHT in OHCA survivors 
is ambiguous and a uniform protocol for the procedure 
is lacking. The Unicorn study is expected to provide 
important information regarding the impact of MTH 
on clinical outcomes in OHCA survivors. Moreover, 
the study will assess whether stratification of patients 
according to concentrations of natriuretic peptides 
(BNP or NTproBNP), ST2, and adrenomedullin provides 
additional information regarding prediction of clinical 
outcomes in OHCA patients.
Contributors
JMK, KP and JK conceived the study. JMK, KP, PA 
and JK and wrote the study protocol with consultation 
from SDS, AK, MG, PK, PP and MK. Subsequently, JMK, 
KP, PA, MK, EO, KO, AD, SDM, AK, MG, PK, PP, MK 
and JK revised the manuscript critically for important 
intellectual content. All the authors read and approved 
the final manuscript.
Funding
The study is funded by Collegium Medicum of 
Nicolaus Copernicus University.
Competing interests
None declared.
Ethics approval
Komisja Bioetyczna Uniwersytetu Mikołaja Koper-
nika w Toruniu przy Collegium Medicum im. Ludwika 
Rydygiera w Bydgoszczy (reference: KB 615/2015).
References
1. Atwood C, Eisenberg MS, Herlitz J et al. Incidence of EMS-treated 
out- of-hospital cardiac arrest in Europe. Resuscitation 2005; 67: 75–80. 
2. Nichol G, Thomas E, Callaway CW et al. Regional variation in out-of-hospi-
tal cardiac arrest incidence and outcome. JAMA 2008; 300: 1423–1431. 
3. Stiell IG, Wells GA, Field B et al. Advanced cardiac life support in out-of-
-hospital cardiac arrest. N Engl J Med 2004; 351: 647–656. 
4. Bernard SA, Gray TW, Buist MD et al. Treatment of comatose survivors 
of out-of- hospital cardiac arrest with induced hypothermia. N Engl J 
Med 2002; 346: 557–563. 
5. The Hypothermia after Cardiac Arrest Study Group. Mild therapeutic hy-
pothermia to improve the neurologic outcome after cardiac arrest. N Engl 
J Med 2002; 346: 549–556.
6. Steg PG, James SK, Atar D et al. ESC guidelines for the management 
of acute myocardial infarction in patients presenting with ST-segment 
elevation: the task force on the management of ST-segment elevation 
acute myocardial infarction of the European society of cardiology (ESC). 
Eur Heart J 2012; 33: 2569–2619.
7. Dumas F, White L, Stubbs BA et al. Long-term prognosis following 
resuscitation from out of hospital cardiac arrest: role of percutaneous 
coronary intervention and therapeutic hypothermia. J Am Coll Cardiol 
2012; 60: 21–27. 
8. Casella G, Carinci V, Cavallo P et al. Combining therapeutic hypothermia 
and emergent coronary angiography in out-of-hospital cardiac arrest 
survivors: Optimal post-arrest care for the best patient. Eur Heart J Acute 
Cardiovasc Care 2015; 4: 579–588.
9. Young-Min K, Hyeon-Woo Y, Seung-Hee J et al. Does therapeutic hypo-
thermia benefit adult cardiac arrest patients presenting with non-shock-
able initial rhythms? A systematic review and meta-analysis of randomized 
and non-randomized studies. Resuscitation 2011; 83: 188–196.
10. Kozinski M, Pstragowski K, Kubica JM et al. ACS network-based im-
plementation of therapeutic hypothermia for the treatment of comatose 
out-of-hospital cardiac arrest survivors improves clinical outcomes: the 
first European experience. Scand J Trauma Resusc Emerg Med 2013; 
21: 547–556. 
11. Nielsen N, Wetterslev J, Cronberg T et al. Targeted temperature man-
agement at 33°C versus 36°C after cardiac arrest. N Engl J Med 2013; 
369: 2197–2206. 
12. Kubica JM, Pstrągowski K, Koziński M et al. Mild therapeutic hypothermia 
for patients with acute coronary syndrome and cardiac arrest treated with 
percutaneous coronary intervention. A single center study [abstract]. Clin 
Chem Lab Med 2014; 52: eA467–eA468.
13. Kubica JM. Mild therapeutic hypothermia for patients with acute coro-
nary syndrome and cardiac arrest treated with percutaneous coronary 
intervention (UNICORN). Research proposal [abstract]. Clin Chem Lab 
Med 2014; 52: eA467.
14. Lassus J, Gayat E, Mueller C et al. Incremental value of biomarkers to 
clinical variables for mortality prediction in acutely decompensated heart 
failure: the Multinational Observational Cohort on Acute Heart Failure 
(MOCA) study. Int J Cardiol 2013; 168: 2186–2194. 
15. Farmakis D, Filippatos G, Tubaro M et al. Natriuretic peptides in acute 
coronary syndromes: prognostic value and clinical implications. Congest 
Heart Fail 2008; 14 (suppl. 1): 25–29. 
16. Richards AM, Di Somma S, Mueller T. ST2 in stable and unstable ischemic 
heart diseases. Am J Cardiol 2015; 115 )suppl. 7): 48B–58B.
